Product Details
Product Name:
Icrucumab |
CAS No.:
1024603-92-6 |
Purity:
> 95% |
Supply Ability:
10g |
Release date:
2024/11/19 |
Product Introduction
Bioactivity
Name | Icrucumab |
Description | Icrucumab ( IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.Icrucumab has antitumor activity.Icrucumab has been studied in metastatic colon cancer. |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Inhibitors Related | Ribociclib | Nintedanib | Regorafenib monohydrate | Taxifolin | Sorafenib | Regorafenib | Sanguinarine chloride | Ponatinib | Sorafenib tosylate | Lenvatinib mesylate | Pazopanib | Axitinib |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1440251-53-5
$44.00 / 1mg
-
CAS:3094-09-5
$94.00 / 5g
-
CAS:13031-04-4
$29.00 / 5mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |